Coiled Therapeutics announced a significant improvement in clinical outcomes for its cancer drug AO-252, with the clinical benefit rate rising from 40% to 80% after switching to twice-daily dosing. This dosing change maintains therapeutic drug levels longer, enhancing efficacy without increasing toxicity. The drug's multimodal action targets tumor cells and activates the immune system, showing promise even in heavily pre-treated late-stage cancer patients. The company plans multiple data readouts and combination trials throughout 2026, aiming to expand AO-252's use across various cancer types.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...
Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...
